Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
复制标题
卡铂和贝伐珠单抗均可提高三阴性乳腺癌新辅助治疗的病理完全缓解率：荟萃分析
DOI：
10.1371/journal.pone.0108405
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Shen KW
中科院分区：
文献类型：
--
作者：
Chen XS;Yuan Y;Garfield DH;Wu JY;Huang O;Shen KW
三阴性乳腺癌（TNBC）在新辅助治疗（NAT）中具有较高的病理完全缓解（pCR）率。获得pCR的TNBC患者的预后优于未获得pCR的TNBC患者。我们进行了一项荟萃分析，以评估将新方法整合到NAT中是否可以提高TNBC的pCR率。采用医学主题词（乳腺肿瘤）和关键词（三阴性或雌激素受体（ER）阴性或HER2阴性）和（原发性全身或新辅助或术前）来选择符合条件的研究。在本荟萃分析中，每项研究中的实验组被定义为测试方案，对照组被定义为标准方案。最终分析共纳入了11项研究和14个配对方案。标准组和检测组的聚合pCR率分别为37.3%和44.6%。与标准方案相比，该试验方案中的新方法显著提高了TNBC患者NAT的pCR率，优势比（OR）为1.34（95%可信区间（CI） 1.11-1.62, P = 0.002）。考虑到特定的方案，我们证明了pCR率在含卡铂方案（OR = 1.80, 95% CI 1.39-2.32， P<0.001）或含贝伐单抗方案（OR = 1.36, 95% CI 1.11-1.66, P = 0.003）中比在对照方案中要高得多。TNBC患者在NAT中加入卡铂的pCR率高达51.2%，与对照方案相比，绝对pCR差异为13.8%。在评估在NAT中添加卡铂或贝伐单抗疗效的研究中，没有发现显著的异质性。这项荟萃分析表明，这些新的NAT方案在TNBC患者中取得了显著的pCR改善，特别是在使用卡铂或贝伐单抗方案治疗的患者中。这可以帮助我们在辅助设置和指导临床实践设计适当的试验。
Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) rate in neoadjuvant treatment (NAT). TNBC patients who achieve pCR have superior outcome than those without pCR. A meta-analysis was done to evaluate whether integrating novel approaches into NAT can improve the pCR rate in TNBC. Medical subject heading terms (Breast Neoplasm) and key words (triple negative OR estrogen receptor (ER) negative OR HER2 negative) AND (primary systemic OR neoadjuvant OR preoperative) were used to select eligible studies. Experimental arm in each study was considered as the testing regimen, and control arm was defined as the standard regimen in this meta-analysis. A total of 11 studies with 14 paired regimens were included in the final analysis. Aggregate pCR rate was 37.3% and 44.6% in the standard and testing group, respectively. Novel approaches in the testing regimen significantly improved the pCR rate in NAT of TNBC patients compared with the standard regimen, with an odds ratio (OR) of 1.34 (95% confidence interval (CI) 1.11–1.62, P = 0.002). Considering specific regimens, we demonstrated the pCR rate to be much higher in the carboplatin-containing (OR = 1.80, 95% CI 1.39–2.32, P<0.001) or bevacizumab-containing regimens (OR = 1.36, 95% CI 1.11–1.66, P = 0.003) than in the control regimens. The addition of carboplatin in NAT had a pCR rate as high as 51.2% in TNBC patients, with an absolute pCR difference of 13.8% as compared with control regimens. No significant heterogeneity was identified among studies evaluating the addition of carboplatin or bevacizumab efficacy in NAT. This meta-analysis indicates that these novel NAT regimens have achieved a significant pCR improvement in TNBC patients, especially among patients treated with carboplatin-containing or bevacizumab-containing regimen. This can help us design appropriate trials in the adjuvant setting and guide clinical practice.
登录
查看更多内容
影响因子：
11.5
作者：
Bardia, Aditya;Baselga, Jose
通讯作者：
Baselga, Jose
DOI：
10.1056/nejmoa1111097
发表时间：
2012-01-26
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bear HD;Tang G;Rastogi P;Geyer CE Jr;Robidoux A;Atkins JN;Baez-Diaz L;Brufsky AM;Mehta RS;Fehrenbacher L;Young JA;Senecal FM;Gaur R;Margolese RG;Adams PT;Gross HM;Costantino JP;Swain SM;Mamounas EP;Wolmark N
通讯作者：
Wolmark N
影响因子：
45.3
作者：
Liedtke, Cornelia;Mazouni, Chafika;Pusztai, Lajos
通讯作者：
Pusztai, Lajos
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.
影响因子：
168.9
作者：
Albain, K.;Anderson, S.;Arriagada, R.;Barlow, W.;Bergh, J.;Bliss, J.;Buyse, M.;Cameron, D.;Carrasco, E.;Clarke, M.;Correa, C.;Coates, A.;Collins, R.;Costantino, J.;Cutter, D.;Cuzick, J.;Darby, S.;Davidson, N.;Davies, C.;Davies, K.;Delmestri, A.;Di Leo, A.;Dowsett, M.;Elphinstone, P.;Evans, V.;Ewertz, M.;Gelber, R.;Gettins, L.;Geyer, C.;Goldhirsch, A.;Godwin, J.;Gray, R.;Gregory, C.;Hayes, D.;Hill, C.;Ingle, J.;Jakesz, R.;James, S.;Kaufmann, M.;Kerr, A.;MacKinnon, E.;McGale, P.;McHugh, T.;Norton, L.;Ohashi, Y.;Paik, S.;Pan, H. C.;Perez, E.;Peto, R.;Piccart, M.;Pierce, L.;Pritchard, K.;Pruneri, G.;Raina, V.;Ravdin, P.;Robertson, J.;Rutgers, E.;Shao, Y. F.;Swain, S.;Taylor, C.;Valagussa, P.;Viale, G.;Whelan, T.;Winer, E.;Wang, Y.;Wood, W.
通讯作者：
Wood, W.